Tronox Ltd (TROX) Forms $13.55 Double Top, Dimension Therapeutics (DMTX) Shorts Raised By 24.07%

June 26, 2017 - By Clifton Ray

Tronox Ltd (TROX) formed double top with $14.36 target or 6.00% above today’s $13.55 share price. Tronox Ltd (TROX) has $914.14M valuation. About 323,842 shares traded. Tronox Ltd (NYSE:TROX) has risen 311.09% since June 26, 2016 and is uptrending. It has outperformed by 294.39% the S&P500.

Dimension Therapeutics Incorporated (NASDAQ:DMTX) had an increase of 24.07% in short interest. DMTX’s SI was 579,900 shares in June as released by FINRA. Its up 24.07% from 467,400 shares previously. With 61,300 avg volume, 10 days are for Dimension Therapeutics Incorporated (NASDAQ:DMTX)’s short sellers to cover DMTX’s short positions. The SI to Dimension Therapeutics Incorporated’s float is 3.35%. About 38,300 shares traded. Dimension Therapeutics Inc (NASDAQ:DMTX) has declined 83.05% since June 26, 2016 and is downtrending. It has underperformed by 99.75% the S&P500.

Among 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Dimension Therapeutics had 9 analyst reports since November 6, 2015 according to SRatingsIntel. The company was initiated on Monday, November 16 by Canaccord Genuity. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) has “Buy” rating given on Monday, November 16 by Citigroup. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, February 18. Goldman Sachs initiated Dimension Therapeutics Inc (NASDAQ:DMTX) on Friday, December 4 with “Buy” rating. On Friday, November 6 the stock rating was initiated by Roth Capital with “Buy”. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The company was initiated on Monday, November 16 by Goldman Sachs. The firm has “Buy” rating given on Friday, June 3 by Cantor Fitzgerald.

Dimension Therapeutics, Inc. is a gene therapy company. The company has market cap of $36.90 million. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It currently has negative earnings. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase deficiency, and glycogen storage disease type Ia (GSDIa).